GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in China

GNI Group ( (JP:2160) ) has shared an announcement.

GNI Group’s subsidiary, Gyre Therapeutics, has initiated a Phase 1 clinical trial in China for F230, a treatment candidate for pulmonary arterial hypertension (PAH). This marks the company’s entry into the PAH market, a rare and life-threatening condition with limited treatment options. The trial aims to assess the safety and pharmacokinetics of F230, a selective endothelin A receptor antagonist, and is part of Gyre’s strategy to expand its fibrosis treatment pipeline. The development is not expected to impact the company’s earnings forecast for the current fiscal year.

The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

More about GNI Group

GNI Group Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative treatments. Its primary products include novel drug candidates for rare diseases, with a market focus in China.

Average Trading Volume: 2,551,524

Technical Sentiment Signal: Buy

Current Market Cap: Yen207.2B

For an in-depth examination of 2160 stock, go to TipRanks’ Stock Analysis page.